Pipeline

Product Therapeutic Area Phase 1 Phase 2 Phase 3 BLA/NDA
Ongoing
Planned

Immunotherapy: Breast Cancer

NeuVax™ - PRESENT Node-positive HER2 IHC 1+/2+
NeuVax™ + Herceptin® Node-positive or node negative/triple negative HER2 IHC 1+/2+
NeuVax™ + Herceptin® High risk, node-positive or negative, HER2 IHC 3+
NeuVax™ - VADIS Ductal Carcinoma in Situ (DCIS)

Immunotherapy: Gastric Cancer

NeuVax™ Gastric, HER2 IHC 1+/2+/3+

Immunotherapy: Gynecological Cancer

GALE-301 Ovarian & Endometrial
GALE-301 + GALE-302 Ovarian & Breast

Hematology

GALE-401 (Anagrelide CR) MPN-related thrombocytosis

*NeuVax™ is an investigational product.  Efficacy has not been established. Herceptin® is a registered trademark of Genentech.